Çѱ¹¹ÙÀÌ¿ÀÀǾàÇ°Çùȸ ´º½º·¹ÅÍ ±¹¹® Å×½ºÆ®ÆÄÀÏ
|
|
|
º¸µµÀÚ·á |
Áö³ÇØ ±¹³» ÀǾàÇ° ½ÃÀå±Ô¸ð ù 20Á¶¿ø ´ë µ¹ÆÄ
- Àü³â´ëºñ ÀǾàÇ° »ý»ê½ÇÀû 10.8%Áõ°¡, ±× Áß ¹ÙÀÌ¿ÀÀǾàÇ° 16.7%Áõ°¡ -
- ¹ÙÀÌ¿ÀÀǾàÇ° ¼öÃâ 31.5% Áõ°¡·Î 2³â ¿¬¼Ó ¹«¿ª¼öÁö ÈæÀÚ ±â·Ï -
¡à ½ÄÇ°ÀǾàÇ°¾ÈÀüó(óÀå ¼Õ¹®±â)´Â Áö³ÇØ ÀǾàÇ°(¹ÙÀÌ¿ÀÀǾàÇ° Æ÷ÇÔ) ½ÃÀå±Ô¸ð´Â ¡®15³â 19Á¶ 2,364¾ï¿ø ´ëºñ 12.9% Áõ°¡ÇÑ 21Á¶ 7,256¾ï¿øÀ¸·Î óÀ½À¸·Î 20Á¶¿ø ´ë¸¦ ³Ñ¾î¼¹À¸¸ç, ¹ÙÀÌ¿ÀÀǾàÇ°µµ »ý»ê½ÇÀû 2Á¶¿øÀ» óÀ½À¸·Î µ¹ÆÄÇß´Ù°í ¹àÇû´Ù.
¡Ø ½ÃÀå±Ô¸ð : »ý»ê-¼öÃâ+¼öÀÔ
¡Ø ¹ÙÀÌ¿ÀÀǾàÇ°: ÈÇÐÀǾàÇ°°ú´Â ´Þ¸® »ç¶÷À̳ª »ý¹°Ã¼¿¡¼ À¯·¡ ¿ø·á¸¦ »ç¿ëÇÏ¿© Á¦Á¶ÇÑ ÀǾàÇ°À¸·Î ¹é½Å, ¼¼Æ÷Ä¡·áÁ¦ µîÀÌ ÀÖÀ½
¡Û ±¹³» ÀǾàÇ° »ý»ê½ÇÀûÀº ¡¯16³â 18Á¶ 8,061¾ï¿øÀ¸·Î ¡¯15³â(16Á¶ 9,696¾ï¿ø) ´ëºñ 10.8% ´Ã¾î³µÀ¸¸ç, ¼öÃâÀº `16³â 31¾ï 2,040¸¸´Þ·¯(3Á¶ 6,209¾ï¿ø)·Î Àü³â(29¾ï 4,726¸¸´Þ·¯, 3Á¶ 3,348¾ï¿ø) ´ëºñ 5.9% Áõ°¡ÇÏ¿´´Ù.
¡Ø »ý»ê½ÇÀû : 15Á¶ 7,140¾ï¿ø(`12³â)¡æ 16Á¶ 3,761¾ï¿ø(`13³â)¡æ 16Á¶ 4,194¾ï¿ø(`14³â)¡æ 16Á¶ 9,696¾ï¿ø(`15³â)¡æ 18Á¶ 8,061¾ï¿ø(`16³â)
¡à Áö³ÇØ ¿ì¸®³ª¶ó ÀǾàÇ°½ÃÀåÀÇ ÁÖ¿äƯ¡Àº ¡ã¿ø·áÀǾàÇ° »ý»ê½ÇÀû Áõ°¡ ¡ãÃÖ±Ù 5³â °£ ÀǾàÇ° ¼öÃâ ¼ºÀå¼¼ À¯Áö ¡ã¹é½Å°ú ºñŸ¹ÎÁ¦ »ý»ê½ÇÀû Áõ°¡ ¡ã»ý»ê½ÇÀû 1À§ ¾÷ü, Á¦Ç° Áö³ÇØ¿Í µ¿ÀÏ µîÀÌ´Ù.
¡à Áö³ÇØ ¹ÙÀÌ¿ÀÀǾàÇ° »ý»ê½ÇÀûÀº óÀ½À¸·Î 2Á¶¿ø¿¡ ÁøÀÔÇÏ¿´À¸¸ç, ¼öÃâµµ 1Á¶¿øÀ» µ¹ÆÄÇÏ¸é¼ ¡®15³â¿¡ ÀÌ¾î ¿¬¼Ó ¹«¿ª¼öÁö ÈæÀÚ¸¦ ±â·ÏÇÏ¿´´Ù.
......´õ º¸±â
|
|
ÇàÁ¤¿¹°í |
¡¸º¹ÇÕ¡¤Á¶ÇÕÇ°¸ñ 󸮱ÔÁ¤¡¹ ÀϺΠ°³Á¤¿¹±Ô¾È ÇàÁ¤¿¹°í
1. °³Á¤ÀÌÀ¯
ÇöÀçÀÇ °úÇÐ ¼öÁØÀ» ¹Ý¿µÇÏ¿© º¹ÇÕ¡¤Á¶ÇÕ Ç°¸ñ¿¡ ´ëÇÑ ºÐ·ù ±âÁØ ¹× ¹Î¿øó¸® ¼¼ºÎÀýÂ÷ µîÀ» ¸¶·ÃÇÏ°í ±× °£ ¿î¿µ»ó ³ªÅ¸³ ÀϺΠ¹ÌºñÁ¡À» °³¼±ÇÏ°íÀÚ ÇÔ
2. ÁÖ¿ä³»¿ë
°¡. º¹ÇÕ¡¤Á¶ÇÕÇ°¸ñÀº ¾Æ´Ï³ª ±âÁ¸ »ç·Ê°¡ ¾ø¾î ºÐ·ù°¡ ºÒºÐ¸íÇÑ Ç°¸ñ¿¡ ´ëÇÑ ºÐ·ù ÀýÂ÷ ½Å¼³(¾È Á¦3Á¶, ¾È Á¦7Á¶)
³ª. ÃÖ±Ù ±â¼úÀ» ¹Ý¿µÇÑ º¹ÇÕ¡¤Á¶ÇÕÇ°¸ñÀÇ ºÐ·ù»ç·Ê Ãß°¡(¾È Á¦4Á¶)
´Ù. Ç°¸ñÁ¶Á¤¼ÒÀ§¿øȸ ½Å¼³(¾È Á¦14Á¶)......´õ º¸±â |
|
|
Áöħ |
LMO ½ÇÇè½Ç ¾ÈÀü°ü¸® Áöħ
LMO(Living Modified Organism, À¯ÀüÀÚº¯Çü»ý¹°Ã¼) °ü·Ã »ý¹°¾ÈÀü ¿øÄ¢°ú ½ÃÇà, »ý¹°¾ÈÀü°ü¸®Ã¼°è ¿î¿µ ¹× ½ÇÇè°èȹ¼ ½É»ç¿¡ °üÇÑ ÁöħÀÌ´Ù. ........ ´õ º¸±â |
|
ȯ°æºÎ
º¸µµÀÚ·á |
³ª°í¾ßÀÇÁ¤¼ ´ç»ç±¹ÀÇ ÀÌÇà °æÇè°ú °úÁ¦
¿ì¸®³ª¶ó´Â ¿À´Â 8¿ù 17ÀÏ ³ª°í¾ßÀÇÁ¤¼ ´ç»ç±¹ÀÌ µÇ¸ç ÀÌ¿¡ µû¶ó ±¹³» ¹ÙÀÌ¿À»ê¾÷°èÀÇ ±¹³»¿Ü »ý¹° ¡®À¯ÀüÀÚ¿øÀÇ Á¢±Ù ¹× ÀÌÀÍ °øÀ¯(ÀÌÇÏ ABS)¡¯ ÀÌÇà Áغñ°¡ ½Ã±ÞÇÑ ½ÇÁ¤ÀÌ´Ù.
Áö³ 7¿ù 6ÀÏ ¼¿ï ¼Ãʱ¸ ´õÄÉÀÌÈ£ÅÚ¿¡¼ ³ª°í¾ßÀÇÁ¤¼ÀÇ ¸ð¹üÀû ÀÌÇà°ú ¹ÙÀÌ¿À»ê¾÷°è Áö¿ø °È¸¦ À§ÇØ '³ª°í¾ßÀÇÁ¤¼ ´ç»ç±¹ÀÇ ÀÌÇà°æÇè°ú °úÁ¦'¸¦ ÁÖÁ¦·Î ±¹Á¦½ÉÆ÷Áö¾öÀÌ °³ÃֵǾú´Ù. À¯ÀüÀÚ¿ø ºÎ±¹ÀÎ Áß±¹, Àεµ, ³²¾ÆÇÁ¸®Ä«°øȱ¹, ¹Ì¾á¸¶ µî°ú À¯ÀüÀÚ¿øÀ» ÁÖ·Î ÀÌ¿ëÇÏ´Â ±¹°¡ÀÎ µ¶ÀÏ, ÀϺ», Çѱ¹ µî ÃÑ 7°³ ±¹°¡ Á¤ºÎ °ü°èÀÚ°¡ ¸ð¿© ±¹°¡º° ³ª°í¾ßÀÇÁ¤¼ ÀÌÇà °ü·Ã ¹ý·ü°ú Á¤Ã¥À» °øÀ¯Çß´Ù..... ´õ º¸±â |
|
|
|
½ÅûÀÚ |
½ÂÀÎÀÏ |
Á¦Ç°¸í |
ÀÓ»ó |
´Ü°è |
(ÁÖ)¸ÞµðÅ彺 |
20170710 |
ÁßµîÁõ ÀÌ»óÀÇ ¿Ü¾È°¢ ÁÖ¸§ °³¼±ÀÌ ÇÊ¿äÇÑ ¼ºÀÎȯÀÚ¸¦ ´ë»óÀ¸·Î ¸ÞµðÅå½ÅÁÖÀÇ À¯È¿¼º°ú ¾ÈÀü¼ºÀ» È®ÀÎÇϱâ À§ÇÑ ¹«ÀÛÀ§¹èÁ¤, ÀÌÁß´«°¡¸², È°¼º¾à´ëÁ¶, ´Ù±â°ü, Á¦1/3»ó ÀÓ»ó½ÃÇè
|
1/3»ó |
ÄÚ¾îÅ彺ÁÖ |
Çѱ¹¿¥¿¡½ºµð(À¯) |
20170710 |
ÁøÇ༺ ¾Ç¼ºÁúȯ ȯÀÚ¸¦ ´ë»óÀ¸·Î MK-8353 + PembrolizumabÀ» Æò°¡ÇÏ´Â Á¦1b»ó ÀÓ»ó½ÃÇè |
1»ó |
1. MK-8353,
2. Pembrolizumab |
Çѱ¹ÈÀÌÀÚÁ¦¾à(ÁÖ) |
20170710 |
50¼¼ ÀÌ»óÀÇ ¼ºÀο¡¼ Ŭ·Î½ºÆ®¸®µã µðÇǽǸ®±Õ ¹é½ÅÀÇ À¯È¿¼º, ¾ÈÀü¼º ¹× ³»¾à¼ºÀ» Æò°¡Çϱâ À§ÇÑ Á¦3»ó, À§¾à´ëÁ¶, ¹«ÀÛÀ§¹èÁ¤, °üÂûÀÚ´«°¡¸² ÀÓ»ó½ÃÇè |
3»ó |
PF-06425090 |
(À¯)Çѱ¹ºñ¿¥¿¡½ºÁ¦¾à |
20170707 |
»õ·Î Áø´ÜµÈ ±Þ¼º °ñ¼ö¼º ¹éÇ÷º´ ´ë»óÀÚ¿¡¼ Àú¿ë·® ½ÃŸ¶óºó°ú º´¿ëÇÑ Ulocuplumab (BMS-936564) ÀÇ Á¦ 1/2»ó, °ø°³, ¹«ÀÛÀ§ ¹èÁ¤ ½ÃÇè |
1/2»ó |
BMS-936564 |
(ÁÖ)¾ÈÆ®·ÎÁ¨ |
20170705 |
´ç´¢º´¼º Á·ºÎ±Ë¾ç ȯÀÚ¿¡°Ô ALLO-ASC-DFUÀÇ À¯È¿¼º°ú ¾ÈÀü¼ºÀ» Æò°¡ÇÏ´Â ¹«ÀÛÀ§¹èÁ¤, ÀÌÁß´«°¡¸², ´ëÁ¶±º ºñ±³, ÆòÇ౺, ´Ù±â°ü Á¦ 3»ó ÀÓ»ó½ÃÇè |
3»ó |
ALLO-ASC-DFU |
Çѱ¹·Î½´ |
201707075 |
¿ø¹ß ħ½À¼º »ïÁß À½¼º À¯¹æ¾Ï ȯÀÚ¿¡¼, ¾ÆÅ×Á¹¸®ÁÖ¸¿ (Ç×PD-L1 Ç×ü) + ¾ÈÆ®¶ó»çÀÌŬ¸°/³À-ÆÄŬ¸®Å¹¼¿À» ±â¹ÝÀ¸·Î ÇÏ´Â Àüº¸Á¶ ÈÇпä¹ý°ú À§¾à + ÈÇпä¹ýÀÇ À¯È¿¼º°ú ¾ÈÀü¼ºÀ» ºñ±³ ¿¬±¸ÇÏ´Â Á¦ 3»ó ¹«ÀÛÀ§¹èÁ¤ ÀÓ»ó½ÃÇè
|
3»ó |
Ƽ½ëÆ®¸¯(RO554-1267) |
|
|
|
|
|
|
|
|
FDA |
|
Drug Name and
FDA Appl. # |
Active Ingredients |
Submission
Classification |
Company |
Approval Date |
OMEPRAZOLE
NDA #209400 |
OMEPRAZOLE |
OTC·Î Àüȯ |
DEXCEL PHARMA |
07/05/2017 |
ENDARI
NDA #208587 |
L-GLUTAMINE |
½ÅÁ¦Çü ¶Ç´Â ½ÅÁ¦Á¶¿ø |
EMMAUS MEDCL |
07/07/2017 |
|
|
|
|
|
|
|
|
Clinical.gov ¹Ì±¹ |
NCT
Number |
Title |
Conditions |
Interventions |
Sponsor
/Collaborators |
Phases |
NCT03211416 |
Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer |
Advanced Adult Hepatocellular Carcinoma|Child-Pugh Class A|Stage III Hepatocellular Carcinoma|Stage IIIA Hepatocellular Carcinoma|Stage IIIB Hepatocellular Carcinoma|Stage IIIC Hepatocellular Carcinoma|Stage IV Hepatocellular Carcinoma|Stage IVA Hepatocellular Carcinoma|Stage IVB Hepatocellular Carcinoma |
Other: Laboratory Biomarker Analysis
Biological: Pembrolizumab
Drug: Sorafenib Tosylate |
Roswell Park Cancer Institute
National Cancer Institute (NCI) |
Phase 1
Phase 2 |
NCT03211247 |
Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Young Children 1-3 Years of Age |
Peanut Allergy |
Biological: Viaskin Peanut 250 mcg
Biological: Viaskin Peanut 100 mcg
Biological: Placebo |
DBV Technologies |
Phase 3 |
NCT03211117 |
Pembrolizumab, Chemotherapy, and Radiation Therapy With or Without Surgery in Treating Patients With Anaplastic Thyroid Cancer |
Thyroid Gland Undifferentiated (Anaplastic) Carcinoma |
Drug: Docetaxel
Drug: Doxorubicin Hydrochloride
Radiation: Intensity-Modulated Radiation Therapy
Other: Laboratory Biomarker Analysis
Biological: Pembrolizumab
Procedure: Therapeutic Conventional Surgery |
Mayo Clinic
National Cancer Institute (NCI) |
Phase 2 |
NCT03210662 |
Pembrolizumab and Fractionated External Beam Radiotherapy (EBRT) in Patients With Non-Hodgkin Lymphoma (NHL) |
Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic|Non-Hodgkin Lymphoma |
Radiation: External Beam Radiotherapy (EBRT)
Drug: Pembrolizumab |
M.D. Anderson Cancer Center
Merck Sharp & Dohme Corp. |
Phase 2 |
|
|
|
Clinical.gov Áß±¹ |
NCT
Number |
Title |
Conditions |
Interventions |
Sponsor
/Collaborators |
Phases |
NCT03209219 |
Interferon ¥á2a Versus Cyclosporine for Refractory Behçet`s Disease Uveitis |
Behçet Disease
Uveitis
|
Drug: Interferon Alfa-2A
Drug: Cyclosporine Pill |
Peking Union Medical College Hospital |
Phase 3 |
|
|
|
|
|
|
Áö³ÇØ ±¹³» ¹ÙÀÌ¿ÀÀǾàÇ° »ý»ê 2Á¶¿ø ÁøÀÔ, ¼öÃâ 1Á¶¿ø µ¹ÆÄ |
¡®16³âµµ ¹ÙÀÌ¿ÀÀǾàÇ° ½ÃÀå±Ô¸ð Àü³â´ëºñ 11.6% Áõ°¡ |
Çѱ¹¹ÙÀÌ¿ÀÀǾàÇ°Çùȸ(´ëÇ¥ ÁÖ±¤¼ö)´Â ½ÄÇ°ÀǾàÇ°¾ÈÀüó¿¡¼ ¹ßÇ¥ÇÑ ¡®16³âµµ ÀǾàÇ° Åë°è ÀڷḦ Åä´ë·Î ÇÏ¿© ±¹³» ¹ÙÀÌ¿ÀÀǾàÇ° ÀÓ»ó½ÃÇèºÎÅÍ Á¦Ç°È´Ü°è±îÁö ÀüÁÖ±âÀû »ê¾÷ ÇöȲÀ» ¹ßÇ¥ÇÏ¿´´Ù. ½ÄÇ°ÀǾàÇ°¾ÈÀüó¿¡ µû¸£¸é, Áö³ÇØ ¹ÙÀÌ¿ÀÀǾàÇ° ½ÃÀå±Ô¸ð´Â ¡®15³â 1Á¶ 6,406¾ï¿ø ´ëºñ 11.6% Áõ°¡ÇÑ 1Á¶ 8,308¾ï¿ø À̾ú´Ù. ±¹³» ¹ÙÀÌ¿ÀÀÇÀǾàÇ° »ý»êÀº ¡®16³â 2Á¶ 79¾ï¿øÀ¸·Î ¡¯15³â(1Á¶ 7,209¾ï¿ø) ´ëºñ 16.7%·Î Å©°Ô Áõ°¡ÇÏ¿´´Ù. ¼öÃâÀº ¡®16³â 10¾ï 6,397¸¸´Þ·¯(1Á¶ 2,346¾ï¿ø)·Î ¡¯15³â(8¾ï 924¸¸´Þ·¯, 9,156¾ï¿ø)´ëºñ 31.5% Áõ°¡ÇÏ¿´°í, ¼öÀÔÀº ¡®16³â ¡®15³â(7¾ï 3,822¸¸´Þ·¯, 8,353¾ï¿ø) ´ëºñ 23.5% Áõ°¡ÇÑ ¡¯16³â 9¾ï 1,139¸¸´Þ·¯(1Á¶ 576¾ï¿ø)À̾ú´Ù.
¡´ ÀÓ»ó½ÃÇè ½ÂÀÎ Áö¼ÓÀû Áõ°¡ ¡µ
¡´ ¼öÃâ ±ÞÁõÀ¸·Î ¼öÃâ 1Á¶¿ø µ¹ÆÄ, 2³â ¿¬¼Ó ¹«¿ª¼öÁö ÈæÀÚ ´Þ¼º ¡µ
¡´ »ý»ê 2Á¶¿ø´ë ÁøÀÔ ¡µ
¡´ ¼öÃâ 1À§ Ç°¸ñ ¡®·¥½Ã¸¶¡¯ ¾àÁø ¡µ
Çѱ¹¹ÙÀÌ¿ÀÀǾàÇ°Çùȸ(´ëÇ¥ ÁÖ±¤¼ö)´Â ±¹³» ¹ÙÀÌ¿ÀÀǾàÇ° »ê¾÷ ¹ßÀüÀ» À§ÇØ Àü¹ÝÀûÀÎ »ê¾÷ µ¿Çâ µî ±¹³» Á¦¾à»ç¿¡ À¯¿ëÇÑ Á¤º¸¸¦ Áö¼ÓÀûÀ¸·Î Á¦°øÇÒ °èȹÀÌ´Ù..... ´õº¸±â
|
|
¹ÙÀÌ¿ÀITÇ÷§Æû '17³â ½Å±ÔÁ¦°øÁ¤º¸ ¾È³» |
¹ÙÀÌ¿ÀITÇ÷§ÆûÀÇ 2017³â ½Å±Ô Á¦°ø Á¤º¸ |
2017³âµµ¿¡´Â Áö³ ÇØ ±ÔÁ¦¡¤»ê¾÷Á¤º¸¸¦ Á¦°øÇÏ¿´´ø 12°³±¹ ¿Ü¿¡ º£Æ®³², Àεµ³×½Ã¾Æ, ÆÄÅ°½ºÅºÀÇ 3°³±¹ Á¤º¸¸¦ Ãß°¡·Î Á¦°øÇÒ ¿¹Á¤ÀÔ´Ï´Ù. ¸¹Àº °ü½É°ú ÀÌ¿ëÀ» ºÎŹ µå¸³´Ï´Ù. |
|
¹ÙÀÌ¿ÀITÇ÷§Æû Àü¹®ÄÁ¼³Æà ¾È³» |
2017³â¿¡´Â ÁÖ¿ä ±Ç¿ª(¹Ì±¹, À¯·´, Áß±¹)º° Àü¹® ÄÁ¼³Æà ¾÷üÀÇ ÀÎÇã°¡ Á¾ÇÕ Áö¿ø ¼ºñ½º(2017 ÷´Ü¹ÙÀÌ¿ÀÀǾàÇ° ÇØ¿ÜÁøÃâ Á¾ÇÕÁö¿ø »ç¾÷ ¡º¹ÙÀÌ¿ÀITÇ÷§Æû¡» Àü¹®ÄÁ¼³ÆÃ)¸¦ »õ·Ó°Ô ½Ç½ÃÇÒ ¿¹Á¤ÀÔ´Ï´Ù. ¸¹Àº ½Åû ¹Ù¶ø´Ï´Ù. |
'Àü¹®ÄÁ¼³ÆÃ' À̶õ? |
¹ÙÀÌ¿ÀÀǾàÇ° ÇØ¿Ü ÀÎÇã°¡ °ü·Ã ¾÷¹«°æÇèÀÌ ÀÖ´Â Àü¹® ÄÁ¼³Æà ±â°üÀÇ
1:1(ÄÁ¼³Æñâ°ü:ÄÁ¼³Æà ÀÇ·Ú ¾÷ü) ÄÁ¼³Æà |
|
|
Èñ¸ÁÇϽô ¾÷ü²²¼´Â Çùȸ ¶Ç´Â ¹ÙÀÌ¿ÀITÇ÷§Æû ȨÆäÀÌÁöÀÇ ¡®¹ÙÀÌ¿ÀITÇ÷§Æû Àü¹®ÄÁ¼³Æà ½Åû¡¤Á¢¼ö °ø°í¡¯¸¦ È®ÀÎÇϽðí,
¡®¹ÙÀÌ¿ÀÀǾàÇ° ÇØ¿ÜÁøÃâ Àü¹®ÄÁ¼³Æà ÀÇ·Ú¼¡¯¸¦ ÀÛ¼ºÇϽþî À̸ÞÀÏ(bpis@kobia.kr) ½Åû¡¤Á¢¼öÇϽñ⠹ٶø´Ï´Ù.
µ¿ÀÏ ±â¾÷Àº ÃÖ´ë 5°Ç±îÁö ½ÉÈ, ¿¬°è ÄÁ¼³ÆÃ(´Ü°èº°) ÀÇ·Ú°¡ °¡´ÉÇÕ´Ï´Ù. |
|
¢º ¹ÙÀÌ¿ÀITÇ÷§Æû Àü¹®ÄÁ¼³Æà °ø°í (»ó½ÃÁ¢¼ö) ¹Ù·Î°¡±â |
|
¢º ¹ÙÀÌ¿ÀITÇ÷§Æû ¹Ù·Î°¡±â |
|
|
|
|
|
|
|
|
Àü½ÃºÎ½º Âü°¡¿¡ °ü½ÉÀÖÀ¸½Å ºÐµéÀº Çùȸ·Î ¿¬¶ô ºÎŹµå¸³´Ï´Ù. ÀÌ¿¬Á¤ (02-725-8438 / yjlee@kobia.kr) |
|
|
|
|
|
|
|
|